Brian Andrew Mitchell Sells 2,000 Shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) Stock

GenMark Diagnostics, Inc (NASDAQ:GNMK) SVP Brian Andrew Mitchell sold 2,000 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $5.05, for a total value of $10,100.00. Following the completion of the transaction, the senior vice president now owns 198,747 shares of the company’s stock, valued at $1,003,672.35. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of GNMK stock opened at $4.69 on Thursday. The stock has a market capitalization of $268.62 million, a PE ratio of -5.15 and a beta of 1.15. GenMark Diagnostics, Inc has a 1-year low of $4.47 and a 1-year high of $8.37. The business has a 50-day moving average of $5.18 and a 200 day moving average of $5.81. The company has a debt-to-equity ratio of 6.40, a current ratio of 2.69 and a quick ratio of 2.11.

GenMark Diagnostics (NASDAQ:GNMK) last issued its earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $20.92 million for the quarter, compared to analysts’ expectations of $20.66 million. GenMark Diagnostics had a negative net margin of 60.63% and a negative return on equity of 239.16%. Analysts anticipate that GenMark Diagnostics, Inc will post -0.81 EPS for the current year.

A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. cut GenMark Diagnostics from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $11.00 to $7.00 in a report on Wednesday, December 11th. Zacks Investment Research cut GenMark Diagnostics from a “hold” rating to a “sell” rating in a report on Wednesday, January 8th. ValuEngine upgraded GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Thursday, December 26th. Finally, BidaskClub upgraded GenMark Diagnostics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 8th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $9.67.

A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in GenMark Diagnostics by 5.3% during the 2nd quarter. BlackRock Inc. now owns 3,809,177 shares of the medical equipment provider’s stock valued at $24,722,000 after acquiring an additional 193,216 shares during the period. Morgan Stanley boosted its holdings in GenMark Diagnostics by 434.0% during the 2nd quarter. Morgan Stanley now owns 1,824,449 shares of the medical equipment provider’s stock valued at $11,841,000 after acquiring an additional 1,482,787 shares during the period. Bank of America Corp DE boosted its holdings in GenMark Diagnostics by 11.2% during the 2nd quarter. Bank of America Corp DE now owns 1,513,795 shares of the medical equipment provider’s stock valued at $9,825,000 after acquiring an additional 152,248 shares during the period. State Street Corp boosted its holdings in GenMark Diagnostics by 4.3% during the 3rd quarter. State Street Corp now owns 1,104,573 shares of the medical equipment provider’s stock valued at $6,694,000 after acquiring an additional 45,566 shares during the period. Finally, Northern Trust Corp boosted its holdings in GenMark Diagnostics by 1.7% during the 2nd quarter. Northern Trust Corp now owns 675,830 shares of the medical equipment provider’s stock valued at $4,386,000 after acquiring an additional 11,530 shares during the period. Institutional investors own 90.84% of the company’s stock.

About GenMark Diagnostics

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Recommended Story: Why do analysts give a neutral rating?

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.